Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations

NCT07711210 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: ACC017
DRUG: Placebo

Sponsor

Jiangsu Aidea Pharmaceutical Group Co., Ltd.